

# AMBEY LABORATORIES LIMITED

CIN: U74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,  
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: [accountho@ambeylab.com](mailto:accountho@ambeylab.com)

[www.ambeylab.com](http://www.ambeylab.com)

Date: 17.09.2024

To,

**The Head – Listing & Compliance**

National Stock Exchange of India Ltd.,  
Exchange Plaza, C-1, Block G,  
Bandra Kurla Complex,  
Bandra (E)  
Mumbai – 400 051

Dear Sir,

**Sub: Submission of Clarification on Segment Details and Signed Financial Results for the Quarter Ended 31-March-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

We refer to your communication dated 13<sup>th</sup> September 2024 regarding the clarification sought from the Company for the quarter ended 31st March 2024, in relation to compliance with Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. The Exchange has highlighted the following matters for clarification: :

**1. *Segment details not submitted.***

**Clarification**

We would like to clarify that the company operates in a single business segment. As disclosed in the financial results, therefore, segment reporting requirements do not apply to our company in accordance with the relevant accounting standards and SEBI guidelines.

**2. *Financial results not signed by authorized signatory/ies.***

**Clarification**

In the Board meeting held on 7<sup>th</sup> September 2024, the Company has approved its financial results and in accordance with Sub-Regulation 2 of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, the Board has authorized Ms. Sarina Gupta, Director of the Company, to sign the financial results for submission to the Stock Exchange.

For your reference and records, we are enclosing a certified copy of the resolution passed in this regard.

Thank you for bringing these matters to our attention. We remain committed to full compliance and prompt resolution of any queries raised by the Exchange.

**For AMBEY LABORATORIES LIMITED**

**RIMPLE** Digitally signed  
by RIMPLE SARIN  
Date: 2024.09.17  
**SARIN** 13:50:18 +0530'

**Rimple Sarin**

**Designation: Company Secretary**

**Membership No.: A66345**

# AMBEY LABORATORIES LIMITED

CIN: U74899DL1985PLC020490

REG. OFFICE: GROUND FLOOR, PROPERTY NO.555 TARLA MOHALLA,  
GHITORNI, SOUTH WEST DELHI-110030 INDIA

Contact: 9899664458, Email: [accountho@ambeylab.com](mailto:accountho@ambeylab.com)

[www.ambeylab.com](http://www.ambeylab.com)

**CERTIFIED TRUE COPY OF THE RESOLUTION PASSED IN THE MEETING OF THE BOARD OF DIRECTORS OF AMBEY LABORATORIES LIMITED HELD ON SATURDAY, 07<sup>TH</sup> DAY OF SEPTEMBER 2024, COMMENCED AT 06:00 P.M. AT THE REGISTERED OFFICE OF THE COMPANY AT GROUND FLOOR, PROPERTY NO. 555 TARLA MOHALLA, GHITORNI, SOUTH WEST DELHI-110030, CONCLUDED AT 7:10 P.M.**

**CONSIDER AND APPROVE THE AUDITED FINANCIAL STATEMENTS OF THE COMPANY FOR THE FINANCIAL YEAR ENDING ON 31<sup>ST</sup> MARCH, 2024.**

**RESOLVED THAT** the Audited Financial Statement comprising of Balance Sheet and cash flow statement as at 31<sup>st</sup> March, 2024 and Profit & Loss Account for the year ended on that date, together with the Notes to Accounts attached thereto and forming part thereof, be and are hereby approved for submission to Statutory Auditors, M/s Kapish Jain & Associates, Chartered Accountants, New Delhi.

**RESOLVED FURTHER THAT** the Balance Sheet as at the 31st March, 2024 and Profit & Loss Account for the year ended on that date, be authenticated in pursuance of provisions of Section 134 of Companies Act, 2013 and Rules framed there under and be signed by Ms. Sarina Gupta, Director, Ms. Rishita Gupta, Director, Ms. Rimple Sarin, Company Secretary and Mr. Sarvar Alam, CFO of the Company.

**RESOLVED FURTHER THAT** the Financial Results for the Half year ended of Financial Year 2023-24 i.e. from the 01st October, 2023 to the 31st March, 2024, as placed before the Board, be and are hereby also approved for the purpose of submission to the Stock Exchange/s and publication in the newspapers in terms of Regulations 33 and 47 of SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 and Ms. Sarina Gupta, Director of the Company, be and is hereby authorized to sign the financial results on behalf of the Company for the aforementioned purposes.

**RESOLVED FURTHER THAT** Ms. Rimple Sarin, Company Secretary, be and is hereby authorized to submit these Audited Annual Accounts of the Financial Year 2023-24 and/or resolutions/s approving such Audited Annual Accounts to the recognized Stock Exchange where the shares of the Company are listed, and/or to any other authority/ies including Registrar of Companies as may be required."

**RESOLVED FURTHER THAT** certified true copy of this Resolution be forwarded whenever required under the signatures of any Director and/or Company Secretary of the Company."

**For AMBEY LABORATORIES LIMITED**

  


**Rimple Sarin**

**Designation: Company Secretary**

**Membership No: A66345**



National Stock Exchange Of India Limited

**Date of** 17-Sep-2024

**NSE Acknowledgement**

<b>Symbol:-</b>	AMBEY
<b>Name of the Company: -</b>	Ambey Laboratories Limited
<b>Submission Type:-</b>	Announcements
<b>Short Description:-</b>	Reply to Clarification- Financial results
<b>Date of Submission:-</b>	17-Sep-2024 02:58:15 PM
<b>NEAPS App. No:-</b>	2024/Sep/11140/11233

Disclaimer : We hereby acknowledge receipt of your submission through NEAPS. Please note that the content and information provided is pending to be verified by NSEIL.